Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study. [electronic resource]
Producer: 20180516ISSN:- 2047-9980
- Adolescent
- Anti-Bacterial Agents -- adverse effects
- Bacteriological Techniques
- Biofilms -- drug effects
- Child
- Child, Preschool
- Clarithromycin -- adverse effects
- Drug Therapy, Combination
- Female
- Humans
- Immunity, Innate -- drug effects
- Immunoglobulins, Intravenous -- adverse effects
- Immunologic Factors -- adverse effects
- Infant
- Japan
- Length of Stay
- Male
- Mucocutaneous Lymph Node Syndrome -- diagnosis
- Multiplex Polymerase Chain Reaction
- Recurrence
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.